Skip to content

Safety and efficacy of Siddha formulations viz., Thiriloga Chenduram and Annabedhi chendhuram in the treatment of Veluppu noi (Iron Deficiency Anaemia).

An Open Label, Randomized Control Proof of Concept Study to Compare the Efficacy of Thiriloga Chendhuram (TC) with Anna Bedhi Chendhuram (ABC; Active Control) in the Treatment of Veluppu Noi (Iron Deficiency Anaemia) in Women of Reproductive Age. - IMR-TC-Anaemia

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046708
Enrollment
46
Registered
2022-10-21
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Thiriloga Chenduram: 400 mg with honey twice daily for 45 days Control Intervention1: Annabedhi Chenduram: 200 mg with honey twice daily for 45 days

Sponsors

Central Council for Research in Siddha Ministry of AYUSH Govt of India Chennai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Haemoglobin level between 6 and 10 gm/dl b. Presence of any four of the following clinical findings i. Serum Iron content below 50 µg/l ii. Serum Ferritin below 30 µg/l iii. Haematocrit/ PCV below 35% iv. TIBC below 200 µg/l v. MCHC level below 34 g/dl vi. MCV level below 80 fl vii. Peripheral blood smear showing Hypochromic & Microcytic Anaemia

Exclusion criteria

Exclusion criteria: a. Pregnant Women & Lactating Mothers b. Severe Renal, Hepatic & Cardiac diseases c. Known case of Diabetes mellitus & Hypertension d. Other clinical conditions like Bleeding Piles, Haemetemesis, Maleana etc, Causing frequent blood loss e. Dimorphic Anaemia

Design outcomes

Primary

MeasureTime frame
i. Safety and Efficacy of the trial drug Thiriloga Chenduram ii. Biochemical changes in Blood and RBC (Before and After treatment)Timepoint: Laboratory Investigations will be performed on 0th, 15th, 30th & 46th day.

Secondary

MeasureTime frame
iii. Substantiate the prognosis of the patient even after therapyTimepoint: Blood investigations will be done on 1st, 3rd and 6th month after the treatment period of 45 days.

Countries

India

Contacts

Public ContactDr K Hina Firdouse

Siddha Regional Research Institute, (Under CCRS, Ministry of AYUSH)

ggsrri16@gmail.com7339272718

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026